Since angiotensin converting enzyme (ACE), which converts angiotensin I into angiotensin II (Karamyan & Speth, 2007a; Moraes et al., 2017; Speth & Karamyan, 2008), is also central in degradation of bradykinin (Byrd et al., 2006; Israili & Hall, 1992), alteration of the RAS function in COVID‐19 could also mean changed activity of the bradykinin system. This evidence concerns the gene ACE and COVID-19.